Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When cisplatin is given before paclitaxel, the beneficial effects of paclitaxel may be decreased. Cisplatin given before paclitaxel may also change how your body processes paclitaxel. This can result in an increase in its toxic effects.
What might happen:
When paclitaxel is given after cisplatin, the beneficial effects and how your body processes paclitaxel may change.
What you should do about this interaction:
If you experience a persistent sore throat or fever, contact your doctor as soon as possible. The dose of your medicines may need adjusting.When used together, paclitaxel is usually given before cisplatin or at the same time. Your healthcare professionals (e.g. doctor or pharmacist) may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dose of any medicine before checking with them first.
1.Liebmann JE, Fisher J, Teague D, Cook JA. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 1994;6(1):25-31.
2.Taxol (paclitaxel) US prescribing information. Bristol-Myers Squibb Company August, 2010.
3.Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994 Feb;69(2):299-306.
4.Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schroder J, Seeber S. Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 1995;31A(1):92-7.
5.Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991 Sep; 9(9):1692-703.
6.Clark JW, Santos-Moore AS, Choy H. Sequencing of taxol and carboplatimum therapy. Proc Am Assoc Cancer Res 1995 Mar;36:298.